Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Objective: To determine the prevalence and characteristics of coronary heart disease (CHD) risk factors in patients with chronic schizophrenia or schizoaffective disorder. Method: We compared individual CHD risk factors and Framingham risk predictions in a group of 240 patients with a large national sample (Canadian Heart Health Survey) matched for age and sex. In addition, we compared rates of the metabolic syndrome (syndrome X) with recently published rates in the US adult population. Results: Compared with the reference population, Framingham 10-year risk of myocardial infarction was greater in the male patients ( t 3091 = 4.35, P < 0.001) but not in the female patients. Prevalence rates of the metabolic syndrome in the patients (42.6% of men and 48.5% of women) were approximately 2 times published rates in the US adult population. Further, the syndrome appears to occur at a younger age than in the general population. Conclusions: These long-term patients have increased CHD risks best captured by the metabolic syndrome conceptualization coupled with a high rate of cigarette smoking. This characterization is consistent with increased cardiovascular morbidity and decreased life expectancy in both men and women. We underscore the importance of both screening for and treating potentially reversible CHD risk factors in schizophrenia patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Smoking cessation for the secondary prevention of coronary heart disease
Critchley, J. A., & Capewell, S. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003041.pub2 · Cited by 342
RetractedRole of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581 · cited 1×
“These risk factors have been incorporated into tables that predict the risk of myocardial infarction (MI) (23).”
BackgroundFord, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
The Continuing Epidemics of Obesity and Diabetes in the United States
Mokdad, A. H. (2001) · JAMA · doi:10.1001/jama.286.10.1195 · Cited by 2,730
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703 · cited 1×
“4% in the general population with similar age distribution, screened in the same manner (34).”
BackgroundAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
The Spread of the Obesity Epidemic in the United States, 1991-1998
Mokdad, A. H. (1999) · JAMA · doi:10.1001/jama.282.16.1519 · Cited by 2,280
Causes of the excess mortality of schizophrenia
Brown, S., Inskip, H., & Barraclough, B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.3.212 · Cited by 1,087
Role of Insulin Resistance in Human Disease (Syndrome X): An Expanded Definition
Reaven, G. M. (1993) · Annual Review of Medicine · doi:10.1146/annurev.me.44.020193.001005 · Cited by 912
The unhealthy lifestyle of people with schizophrenia
BROWN, S., BIRTWISTLE, J., ROE, L., & THOMPSON, C. (1999) · Psychological Medicine · doi:10.1017/s0033291798008186 · Cited by 874
Excess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869
Mortality and causes of death in schizophrenia in Stockholm County, Sweden
Ösby, U., Correia, N., Brandt, L., Ekbom, A., & Sparén, P. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00191-7 · Cited by 679 · cited 3×
“4) for women who received a first hospital diagnosis of schizophrenia from 1973 to 1995 in Stockholm County, Sweden (8).”
BackgroundResultInfluentialMedical Comorbidity in Schizophrenia
Jeste, D. V., Gladsjo, J. A., Lindamer, L. A., & Lacro, J. P. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.3.413 · Cited by 624
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1189 · Cited by 579
Prevalence and Correlates of Diabetes in National Schizophrenia Samples
Dixon, L., Weiden, P., Delahanty, J., Goldberg, R., Postrado, L., Lucksted, A., & Lehman, A. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033504 · Cited by 569
Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia
Newcomer, J. W., Haupt, D. W., Fucetola, R., Melson, A. K., Schweiger, J. A., Cooper, B. P., & Selke, G. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.4.337 · Cited by 520
Lemieux, S., Prud’homme, D., Bouchard, C., Tremblay, A., & Després, J. (1996) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/64.5.685 · Cited by 472
Self-citationAtypical antipsychotics and weightgain — a systematic review
Taylor, D. M., & McAskill, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101006416.x · Cited by 433
Mortality and Causes of Death in First Admitted Schizophrenic Patients
Mortensen, P. B., & Juel, K. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.163.2.183 · Cited by 412
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407
Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study*
Newman, S. C., & Bland, R. C. (1991) · The Canadian Journal of Psychiatry · doi:10.1177/070674379103600401 · Cited by 371
Diabetes mellitus in schizophrenic patients
Mukherjee, S., Decina, P., Bocola, V., Saraceni, F., & Scapicchio, P. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90054-1 · Cited by 368
The Association of Medical Comorbidity in Schizophrenia with Poor Physical and Mental Health
DIXON, L., POSTRADO, L., DELAHANTY, J., FISCHER, P. J., & LEHMAN, A. (1999) · The Journal of Nervous & Mental Disease · doi:10.1097/00005053-199908000-00006 · Cited by 360
Schizophrenia: A Life-shortening Disease
Allebeck, P. (1989) · Schizophrenia Bulletin · doi:10.1093/schbul/15.1.81 · Cited by 335
The Effects of Novel Antipsychotics on Glucose and Lipid Levels
Wirshing, D. A., Jennifer A., J. A., Meng, L. R., Ballon, J. S., Marder, S. R., & Wirshing, W. C. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1002 · Cited by 294
Kromhout, D., Menotti, A., Kesteloot, H., & Sans, S. (2002) · Circulation · doi:10.1161/hc0702.103728 · Cited by 251
Mortality in Schizophrenia: A Ten-Year Follow-up Based on the Stockholm County Inpatient Register
Allebeck, P. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800070036005 · Cited by 183
Weight gain from novel antipsychotic drugs: need for action
Green, A. I., Patel, J. K., Goisman, R. M., Allison, D. B., & Blackburn, G. (2000) · General Hospital Psychiatry · doi:10.1016/s0163-8343(00)00081-5 · Cited by 170
Novel Antipsychotics and Severe Hyperlipidemia
Meyer, J. M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00003 · Cited by 168
Atypical antipsychotics and hyperglycaemia
Mir, S. A., & Taylor, D. M. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200103000-00001 · Cited by 139
Excess mortality among psychiatric patients. The Iowa Record-Linkage Study
Black, D. W. (1985) · JAMA · doi:10.1001/jama.253.1.58 · Cited by 137
Clozapine-Associated Elevation in Serum Triglycerides
Gaulin, B. D., Markowitz, J. S., Caley, C. F., Nesbitt, L. A., & Dufresne, R. L. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1270 · Cited by 131
Physical activity in the prevention of atherosclerotic coronary heart disease
Thompson, P. D., & Lim, V. (2003) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-003-0027-7 · Cited by 29
Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents
Henderson, D. C. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0072-8 · Cited by 26
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140
Metabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634
Physical illness and schizophrenia: a review of the literature
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01095.x · Cited by 633
Nasrallah, H. A., Meyer, J. M., Goff, D. C., McEvoy, J. P., Davis, S. M., Stroup, T. S., & Lieberman, J. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.026 · Cited by 556
Metadata
- Authors
- Cohn, T., Prud'homme, D., Streiner, D., Kameh, H., & Remington, G.
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2004-11
- Volume
- 49
- Issue
- 11
- Pages
- 753-760
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W2147425510
- Cited by
- 254
- References
- 35
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.